COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research.
With in-person teaching in hospital and clinic settings suspended as the COVID-19 pandemic emerged, Weill Cornell Medical College swiftly designed innovative telehealth courses that enabled medical students to take part in remote patient care while also positioning them for post-pandemic careers with expanded digital healthcare options.
Women who receive COVID-19 mRNA vaccines produced by Pfizer-BioNTech or Moderna while in their third trimester of pregnancy generate a strong immune response and pass protective antibodies through umbilical cord blood to their babies.
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.
A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.
Cases of symptomatic COVID-19 were extremely low among children and staff at a network of YMCA day camps in North Carolina that took precautions like masking and physical distancing, with close to zero transmissions occurring at the camps.
T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus’s function.
When a patient is hospitalized with COVID-19, signs of damage to the right side of the heart may indicate a greater risk of death, according to a study from investigators at Weill Cornell Medicine and NewYork-Presbyterian.